Belite Bio Inc ADR BLTE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $136.62
- Day Range
- $135.00–139.85
- 52-Week Range
- $56.10–200.00
- Bid/Ask
- $136.80 / $137.35
- Shares Outstanding
- 40.09M
- Market Cap
- $5.50B
- Volume/Avg
- 179,869 / 170,919
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 41
- Website
- https://www.belitebio.com
Valuation
|
Metric
|
BLTE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.15 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BLTE
|
|---|---|
Quick Ratio | — |
Current Ratio | — |
Interest Coverage | — |
Quick Ratio
BLTE
Profitability
|
Metric
|
BLTE
|
|---|---|
Return on Assets (Normalized) | −20.56% |
Return on Equity (Normalized) | −21.01% |
Return on Invested Capital (Normalized) | −21.00% |
Return on Assets
BLTE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Jhwdgjql | Dndpbl | $111B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mglhxqln | Wthxxx | $63B | |||
| argenx SE ADR
ARGX
| Zqgyygpy | Wqzq | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Bdgjxyd | Vrmyv | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Yvvnytfz | Wwlxw | $24B | |||
| BioNTech SE ADR
BNTX
| Rrckwzvy | Mmrs | $22B | |||
| Incyte Corp
INCY
| Dsprnmy | Gzz | $21B | |||
| Moderna Inc
MRNA
| Pmthxjhd | Lpxs | $18B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Lxpbjsls | Pdr | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Mpyjmqkk | Wvjg | $13B |
United States